ArticleMolecular medicine reports2017
MicroRNA‑137 has a suppressive role in liver cancer via targeting EZH2.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- Retraction: Methylation-induced downregulation and tumor suppressive role of microRNA-29b in gastric cancer through targeting LASP1.Oncotarget · 2023Article
- Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.Journal of oncology · 2022Review
- MicroRNA-214 enriched exosomes from human cerebral endothelial cells (hCEC) sensitize hepatocellular carcinoma to anti-cancer drugs.Oncotarget · 2021Article
- Review
- Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review.International journal of molecular sciences · 2020Review
- MicroRNA‑137 exerts protective effects on hypoxia‑induced cell injury by inhibiting autophagy/mitophagy and maintaining mitochondrial function in breast cancer stem‑like cells.Oncology reports · 2020Article
- Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis.Oncology reports · 2020Article
- MiR-137 promotes anoikis through modulating the AKT signaling pathways in Pancreatic Cancer.Journal of Cancer · 2020Article
- EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma.PloS one · 2020Article
- miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.Oncogene · 2019Article
- Integrated analysis of competing endogenous RNA network revealing potential prognostic biomarkers of hepatocellular carcinoma.Journal of Cancer · 2019Article
- Enhancer of Zeste Homologue 2 Inhibition Attenuates TGF-β Dependent Hepatic Stellate Cell Activation and Liver Fibrosis.Cellular and molecular gastroenterology and hepatology · 2019Article
- Epigenetic Regulation of EMT (Epithelial to Mesenchymal Transition) and Tumor Aggressiveness: A View on Paradoxical Roles of KDM6B and EZH2.Epigenomes · 2018Review
- The Role of MicroRNAs in Hepatocellular Carcinoma.Journal of Cancer · 2018Review
Corrections and comments
- Correction · 2018-03-20Error in Text · Updated to Retraction ·
- Retraction · 2022-03-01Author Unresponsive · Duplication of/in Image · Paper Mill · Upgrade/Update of Prior Notice(s) ·
- Erratum issued
- Retracted
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A variety of microRNAs (miRs) have been demonstrated to be associated with the development and malignant progression of human cancer; however, the regulatory mechanism of miR‑137 underlying hepatocellular carcinoma (HCC) growth and metastasis still remains to be fully revealed. In the present study, reverse transcription‑quantitative polymerase chain reaction and western blot were used to examine mRNA and protein expression. MTT assay, wound healing assay and Transwell assay were performed to determine cell proliferation, migration and invasion. Luciferase reporter assay was conducted to confirm the targeting relationship. miR‑137 was significantly downregulated in HCC tissues compared to adjacent normal tissues. Low expression of miR‑137 was significantly associated with lymph node metastasis, vein invasion, advanced clinical stage and poor prognosis in HCC. In addition, miR‑137 was also downregulated in several liver cancer cell lines compared with normal liver epithelial cells. Overexpression of miR‑137 led to a significant reduction in cell proliferation, migration and invasion of HepG2 cells. Enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) was further identified as a direct target gene of miR‑137, and the protein expression of EZH2 was negatively regulated by miR‑137 in HepG2 cells. Additionally, EZH2 was significantly upregulated in HCC tissues and liver cancer cell lines. Furthermore, overexpression of EZH2 significantly eliminated the inhibitory effects of miR‑137 on the malignant phenotypes of HepG2 cells. Therefore, the findings suggest that miR‑137 may have a suppressive role in HCC growth and metastasis via targeting EZH2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.